Position in BCYC
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$214,705
-$116,117 QoQ
Shares Held
50,638
-29.0% QoQ
Ownership
0.072%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#46
of 103 holders
Holding Since
Dec 2023
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in BCYC Over Time
Shares Held
Position Value (USD)
Derivatives in BCYC
reported options exposure · as of Dec 31, 2023CallValue
$0
CallShares
0
PutValue
$978,128
PutShares
54,100
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026ADAR1 Capital Management, LLC holds $1,760,528,411 across 192 Biotechnology names. BCYC ranks #173 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABVX |
Abivax S.A.
|
1,804,703 | $240,494,721 | |
| 2 | PTGX |
Protagonist Therapeutics, Inc
|
960,863 | $117,782,586 | |
| 3 | ROIV |
Roivant Sciences Ltd.
|
3,157,008 | $111,726,513 | |
| 4 | IMVT |
Immunovant, Inc.
|
2,330,716 | $89,802,487 | |
| 5 | ZLAB |
Zai Lab Ltd
|
3,369,034 | $64,011,646 | |
| 6 | AGIO |
Agios Pharmaceuticals, Inc.
|
1,288,053 | $47,799,646 | |
| 7 | CRNX |
Crinetics Pharmaceuticals, Inc.
|
1,222,080 | $45,730,233 | |
| 8 | CYTK |
Cytokinetics Inc
|
457,907 | $39,009,097 |
All Filings in BCYC
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $214,705 | 50,638 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $330,822 | 71,298 | Shares | Sole | 2026-05-18 | |
| 2024-03-31 | $359,307 | 14,430 | Shares | Sole | 2024-05-15 | |
| 2023-12-31 | $1,352,836 | 74,825 | Shares | Sole | 2024-02-14 | |
| 2023-12-31 | $978,128 | 54,100 | Put | Sole | 2024-02-14 | |
| No filing history on record for this holder in this stock. | ||||||